Retatrutide Cardiovascular Outcomes Trial Reaches Full Enrollment

What is the retatrutide cardiovascular outcomes trial testing?

TRIUMPH-Outcomes, registered as NCT06383390, is designed to answer a question that weight-loss trials cannot: whether retatrutide reduces the rate of serious heart-related complications or prevents worsening kidney function in adults living with obesity. According to the ClinicalTrials.gov record, that is the stated main purpose of the study. The sponsor is Eli Lilly and Company, and the trial is listed as phase 3.

This is a different kind of endpoint from the body-weight percentages that dominate coverage of incretin drugs. An outcomes trial counts events — heart attacks, strokes, cardiovascular deaths, measurable declines in kidney filtration — over years, in a population large enough for those events to accumulate. It is slower, more expensive, and far more consequential for how a drug is eventually labeled and reimbursed.

The registry record does not publish interim results, and none should be inferred from the status change. What changed on August 24 is administrative: the study moved to ACTIVE_NOT_RECRUITING, the designation used when a trial has finished enrolling participants but is still following the ones it has.

Who is enrolled, and how long does the study run?

The enrollment figure listed is 10,000 participants. Eligibility, as described in the registry entry, requires adults with a body mass index of 27 kg/m2 or higher who also have atherosclerotic cardiovascular disease, chronic kidney disease, or both. Atherosclerotic cardiovascular disease covers established plaque-driven conditions such as prior heart attack, stroke, or peripheral artery disease; chronic kidney disease means sustained reduced kidney function.

That inclusion criteria matters for interpreting whatever comes out. This is a secondary-prevention population — people who already have documented cardiovascular or renal disease — not a general population of people using an anti-obesity medication cosmetically. Findings in a higher-risk group do not automatically transfer to a lower-risk one, and the eventual publication will need to be read with that in mind.

The study is described as lasting about five years, with up to 27 clinic visits per participant with the study doctor. Enrollment closing in mid-2026 means the follow-up period, not the recruitment period, is now the rate-limiting step. Anyone waiting on a definitive answer about retatrutide and cardiovascular risk is waiting on years, not months.

For readers already tracking an investigational protocol under provider direction, the retatrutide dosage calculator handles the unit arithmetic that reconstituted vials require.

The Columbia University HFpEF study listing describes a 50-participant phase 4 cohort tracking plasma volume and body composition over 15 months in patients treated with tirzepatide. the Columbia University HFpEF study listing.

What is retatrutide, and where does it sit in the pipeline?

Retatrutide is an investigational agonist that acts at three receptors — GIP, GLP-1, and glucagon — which is why it is usually described as a triple agonist. That distinguishes it from semaglutide, a single GLP-1 receptor agonist marketed as Ozempic and Wegovy, and from tirzepatide, the dual GIP/GLP-1 agonist marketed as Mounjaro and Zepbound. The glucagon component is the novel piece, and the part with the least accumulated long-term human safety data.

It is important to be precise about status: retatrutide is not approved by the U.S. Food and Drug Administration for any indication. It is not available by prescription, it is not on any FDA shortage list, and there is no legitimate compounded version of it, because compounding pharmacies work from approved drug substances. Material sold online as retatrutide sits entirely outside that framework.

The TRIUMPH program is the umbrella name for Lilly's phase 3 retatrutide studies, and the outcomes trial is the largest of them. A drug can succeed on weight reduction and still fail to show a cardiovascular or renal benefit; the two questions are separate, and regulators treat them separately when deciding what a label may claim.

Because the glucagon component of triple agonists has the shortest human track record, consistent side-effect logging is the part of a protocol record most likely to be useful at a follow-up appointment.

Why cardiovascular and kidney endpoints matter for incretin drugs

The commercial and clinical center of gravity in this drug class has shifted from weight to organ outcomes. Payers have been more willing to cover incretin therapies when there is evidence of reduced cardiovascular events rather than reduced body weight alone, and prescribing guidance follows the same logic. A trial powered for cardiovascular and kidney endpoints is, in effect, a bid to move retatrutide from a weight-management drug into cardiometabolic disease management.

Kidney endpoints are the newer addition. Slowing the decline of estimated glomerular filtration rate — the standard measure of how well kidneys filter blood — is a hard endpoint that takes years to demonstrate. Including it alongside cardiovascular events in a single 10,000-person trial is a design choice that signals how broadly Lilly intends to position the compound if the data support it.

If the distinction between a trial regimen and a personal regimen is unclear, our glossary entry on what a protocol is sets out the terms used throughout this coverage.

What else moved in the incretin trial registry this week

Two other registry entries updated in the same window are worth noting for context. Novo Nordisk's study of NNC0174-1213, listed as NCT06719011, is now marked COMPLETED. It was a phase 1 trial with 178 participants with overweight or obesity, randomizing them to the new investigational compound, to cagrilintide — an amylin analogue Novo has been developing in combination with semaglutide — or to placebo. Phase 1 studies assess safety and how the body handles a compound; they are not efficacy trials.

Separately, Columbia University is recruiting for a 50-participant phase 4 study of tirzepatide in patients with obesity and heart failure with preserved ejection fraction, or HFpEF. The stated hypothesis is that tirzepatide reduces measured plasma volume, with serial body composition measurement by quantitative magnetic resonance over 15 months. It is a mechanism study in an approved drug, not a licensing trial, but it reflects the same push toward cardiac endpoints.

Taken together, the three records sketch where the field is going: earlier-phase competition on new molecules at Novo, late-phase outcomes bets at Lilly, and investigator-initiated mechanism work on drugs already in pharmacies.

According to the TRIUMPH-Outcomes registry entry, the phase 3 study has an enrollment of 10,000 adults and is sponsored by Eli Lilly and Company.

What remains unresolved

Nothing about efficacy or safety can be read from an enrollment-status change. Full enrollment tells you the trial recruited the participants it planned to recruit; it says nothing about how they are doing. Adverse event data, discontinuation rates, and any signal on the glucagon component of retatrutide will come out through the trial's eventual publication and any regulatory submission that follows.

The other open question is what happens in the gap. A five-year outcomes trial creates a long window in which retatrutide is widely discussed, widely sold in unregulated channels, and not evaluated by any regulator. That gap is where most of the real-world risk for this audience sits, and no registry update changes it.

The completed phase 1 record for NNC0174-1213 lists 178 participants randomized to the investigational compound, to cagrilintide, or to placebo. the completed phase 1 record for NNC0174-1213.